Search Results - FIRST AID

1

by A. V. Rudakova, D. A. Gusev, A. N. Uskov, Yu. V. Lobzin
Published 2016-02-01

“...Updated HCV clinical guidelines placed direct acting agents (DAAs) as the preferable the first line...”

Get full text

Article

2

by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Published 2016-04-01

“... prices.Results. In the base case costs on antiviral products with narlaprevir as first-line therapy are lower...”

Get full text

Article

3

by D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Published 2016-11-01

“... with narlaprevir as first-line therapy will decrease compared with simeprevir by 22,8% (542,0 and 702,5 thousand...”

Get full text

Article

4

by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Published 2017-06-01

“... with the compensated cirrhosis, now purpose of a PTV/OBV/DSV/r ± RBV in the first line of therapy is the most...”

Get full text

Article

Narrow Search